Keros Therapeutics (KROS) Equity Ratio (2019 - 2025)
Keros Therapeutics (KROS) has disclosed Equity Ratio for 7 consecutive years, with 0.9 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio fell 3.37% year-over-year to 0.9, compared with a TTM value of 0.9 through Dec 2025, down 3.37%, and an annual FY2025 reading of 0.9, down 3.37% over the prior year.
- Equity Ratio was 0.9 for Q4 2025 at Keros Therapeutics, down from 0.95 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.97 in Q2 2021 and bottomed at 0.9 in Q4 2025.
- Average Equity Ratio over 5 years is 0.93, with a median of 0.94 recorded in 2025.
- The sharpest move saw Equity Ratio surged 334.82% in 2021, then dropped 5.08% in 2022.
- Year by year, Equity Ratio stood at 0.95 in 2021, then fell by 5.08% to 0.9 in 2022, then dropped by 0.72% to 0.9 in 2023, then increased by 3.36% to 0.93 in 2024, then fell by 3.37% to 0.9 in 2025.
- Business Quant data shows Equity Ratio for KROS at 0.9 in Q4 2025, 0.95 in Q3 2025, and 0.93 in Q2 2025.